FOR IMMEDIATE RELEASE:
PrimeraDx Names Robert J. Rosenthal, Ph.D., Director to the Board
Mansfield, MA — February 24, 2008 — PrimeraDx today announced it named Robert J. Rosenthal, Ph.D. to the Board of Directors as an independent outside Director and member of the Audit Committee.
“We are very pleased with Dr. Rosenthal joining the Board. His experience and knowledge are very important to PrimeraDx and I look forward to his contributions,” said Martin L. Verhoef, President and CEO of PrimeraDx.
Dr. Rosenthal commented, “I am very pleased to join PrimeraDx. I believe the company’s proprietary STAR technology will play a major role in personalized medicine and can truly revolutionize molecular diagnostics.”
Dr. Rosenthal is Magellan Biosciences’ founding president and chief executive officer and has 20 years of experience building value for customers, shareholders and employees in companies serving the biomedical research and diagnostics industries. Previously, Dr. Rosenthal was president and CEO of Boston Life Sciences, an R&D development-stage biopharmaceutical company, and president of PerkinElmer's Instruments division, where he managed the acquisition and integration of the Analytical Instruments group from PECorporation.
As president and CEO of Thermo Optek, Dr. Rosenthal built a market-leading instrument company, which went public in 1996. Prior to Thermo Optek, Dr. Rosenthal served as president of Nicolet Instrument Corporation, a subsidiary of Thermo Instruments. In addition to the Magellan and subsidiary Boards, Dr. Rosenthal serves on Safeguard Scientifics, Inc., a holding company that builds value in growth-stage technology and life sciences businesses, and the University of Maryland Department of Chemistry and Biochemistry Board of Advisors. He is also a member of the University of Maryland, College of Chemical and Life Sciences Board of Visitors.
Dr. Rosenthal holds a BS in chemistry from the University of Maryland, an MS in chemistry from State University of New York (Buffalo), and a Ph.D. in physical chemistry from Emory University. He spent a year in Germany completing a post-doctoral fellowship and as a guest scientist of the Alexander von Humboldt Foundation. This was followed by an additional post-doctoral fellowship at UCLA. Dr. Rosenthal also holds an AEA Executive MBA from Stanford University.
PrimeraDx is dedicated to the emerging field of molecular diagnostics. The company is developing multiplexed, quantitative and cost effective assays using its proprietary STAR technology implemented on the ICEPlex instrument platform. STAR combines quantitative PCR with the ability to multiplex up to 60 targets in a single sample. The Company’s initial products are for infectious disease management. PrimeraDx plans to extend its focus into oncology to support cancer therapy management through diagnostic, prognostic, staging and therapeutic monitoring. The Company’s website is: www.primeradx.com.